Interpace Diagnostics Group Inc (IDXG, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Interpace Diagnostics Group Inc is engaged in developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for diagnosis and management. Interpace Diagnostics Group Inc has a market cap of $25.630 million; its shares were traded at around $0.95 with and P/S ratio of 0.62. Interpace Diagnostics Group Inc had annual average EBITDA growth of 20.20% over the past ten years.
For the last quarter Interpace Diagnostics Group Inc reported a revenue of $4.37 million, compared with the revenue of $3.12 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $15.9 million, an increase of 21.5% from last year. For the last five years Interpace Diagnostics Group Inc had an average revenue decline of 36.3% a year.
The reported loss per diluted share was 77 cents for the year, compared with the loss per share of $3.1 in the previous year. The Interpace Diagnostics Group Inc had an operating margin of -39.59%, compared with the operating margin of -49.23% a year before. The 10-year historical median operating margin of Interpace Diagnostics Group Inc is -35.98%. The profitability rank of the company is 3 (out of 10).
At the end of the fiscal year, Interpace Diagnostics Group Inc has the cash and cash equivalents of $15.2 million, compared with $0.60 million in the previous year. The company had no long term debt, compared with $7.91 million in the previous year. Interpace Diagnostics Group Inc has a financial strength rank of 7 (out of 10).
At the current stock price of $0.95, Interpace Diagnostics Group Inc is traded at 12.8% discount to its historical median P/S valuation band of $1.09. The P/S ratio of the stock is 0.62, while the historical median P/S ratio is 0.71. The stock lost 65.21% during the past 12 months.
For the complete 20-year historical financial data of IDXG, click here.
